IDEOlogy Health and Texas Oncology announce collaboration to advance medical education in oncology
Share Article
IDEOlogy Health and Texas Oncology announced today that the two companies have entered a formal agreement to collaborate on expanding and enhancing medical education for Texas Oncology physicians.
“This new relationship will further enhance the skills and expertise of our highly-trained physicians who provide healthcare across a large geographic footprint,” said R. Steven Paulson, M.D., president, and chairman of Texas Oncology. AUSTIN, Texas (PRWEB) May 10, 2021
IDEOlogy Health and Texas Oncology announced today that the two companies have entered a formal agreement to collaborate on expanding and enhancing medical education for Texas Oncology physicians.
Tisotumab for Advanced Cervical Cancer Awaiting Approval medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
ii
80% (n=64)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response
i Includes patients with =1 postbaseline scan or who discontinued treatment.
ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5).
iii DCR is CR+PR+SD
iv Preliminary PFS limited by earlier censoring by data cutoff due to immature duration of follow-up for 4 and 6 mg/kg dose cohorts.
Search jobs 11-Dec-2020 Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer
LOS ANGELES, Calif., December 11, 2020 / B3C newswire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncology Research, an
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in